moving up, page-10

Good to see the SP holding up today - given the delay in filing the second NDA for Omapro and the recent run up.

LifeSci Advisors were on the ball anyway. In their coverage they noted that the filing for NDA was expected to be mid 2011.

From their report:
Upcoming Milestones
? mid 2011: New ?Third-line? NDA expected to be filed for OMAPRO
? 1Q 2011: Expected approval for OMAPRO in T315I patients in Europe
? 4Q 2011: Expected FDA approval of OMAPRO (Priority Review) and possible panel